Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 3/20 | 0.55 |
| ▸ | PI4KA | P42356 | 3/20 | 0.50 |
| ▸ | PI4K2B | Q8TCG2 | 3/20 | 0.50 |
| ▸ | PI4K2A | Q9BTU6 | 3/20 | 0.50 |
| ▸ | PI4KB | Q9UBF8 | 3/20 | 0.50 |
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA2B | P29275 | 2/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 2/20 | 0.50 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.48 |
| ▸ | PIK3CD | O00329 | 2/20 | 0.45 |
| ▸ | PIK3R1 | P27986 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | KDR | P35968 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2153006 | 0.80 | AHCY (0.52) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5360808 | 0.76 | ADORA2A (0.59) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13269011 | 0.74 | ADORA2A (0.65) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL134910 | 0.74 | EGFR (0.61) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL13268766 | 0.74 | ADORA2A (0.65) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL4245944 | 0.72 | ADORA2A (0.58) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL5049210 | 0.72 | ADORA2A (0.63) | PI4KAPI4K2BPI4K2API4KBADORA2A | |
| SCHEMBL9373702 | 0.71 | PI4KA (0.60) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL28018567 | 0.71 | PI4KA (0.56) | EGFRPI4KAPI4K2BPI4K2API4KB | |
| SCHEMBL22474983 | 0.71 | ADORA2A (0.69) | PI4KAPI4K2BPI4K2API4KBADORA2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7115738-B2 | Hydroxyproline/phosphono oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF (US) | 2006-10-03 | — | — | US | disclosed |
| US-6962906-B2 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF (US) | 2005-11-08 | — | — | US | disclosed |
| EP-1263773-A4 | OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE | ACTIVE MOTIF (US) | 2005-08-31 | — | — | EP | disclosed |
| EP-1481085-A2 | OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION | Active Motif (US) | 2004-12-01 | — | — | EP | disclosed |
| US-20040014644-A1 | Oligonucleotide analogues and methods of use for modulating gene expression | ACTIVE MOTIF. | 2004-01-22 | — | — | US | disclosed |
| WO-2003068798-A2 | OLIGONUCLEOTIDE ANALOGUES AND METHODS OF USE FOR MODULATING GENE EXPRESSION | ACTIVE MOTIF (US) | 2003-08-21 | — | — | WO | disclosed |
| US-20030059789-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2003-03-27 | — | — | US | disclosed |
| EP-1263773-A1 | OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE | Active Motif (US) | 2002-12-11 | — | — | EP | disclosed |
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | ACTIVE MOTIF | 2002-10-24 | — | — | US | disclosed |
| WO-2001068673-A1 | OLIGONUCLEOTIDE ANALOGUES, METHODS OF SYNTHESIS AND METHODS OF USE | ACTIVE MOTIF (US) | 2001-09-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020155989-A1 | Oligonucleotide analogues, methods of synthesis and methods of use | HIRA, PHAX, SSU72 | EGFR 3441/4885PI4KA 2541/4885PI4K2B 3407/4885 |
| US-20040014644-A1 | Oligonucleotide analogues and methods of use for modulating gene expression | CRYAA, SRRT, HIRA | EGFR 4515/4885PI4KA 4193/4885PI4K2B 4400/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.